Futura Medical ( (GB:FUM) ) has shared an update.
Futura Medical plc has appointed Harmesh Suniara as a Non-executive Director to its Board, effective immediately. With over 17 years of investment management experience, Suniara’s addition is expected to strengthen Futura’s strategic direction as it continues to address unmet demands in the sexual health market. This appointment is significant given that Lombard Odier Asset Management, where Suniara is a Portfolio Manager, holds a substantial share in Futura Medical, indicating a strong alignment of interests and potential positive impact on the company’s market positioning.
More about Futura Medical
Futura Medical plc is a consumer healthcare company specializing in the development and global commercialization of innovative and clinically proven sexual health products. Their core strength lies in research, development, and commercialization of topically delivered gel formulations, with products such as Eroxon®, WSD4000, and Eroxon® Intense. The company addresses significant unmet needs in the sexual health market, particularly with its lead product Eroxon®, a topical gel for Erectile Dysfunction (ED) that is available over the counter and acts within ten minutes.
YTD Price Performance: -66.95%
Average Trading Volume: 692,676
Technical Sentiment Signal: Buy
Current Market Cap: £31.78M
For an in-depth examination of FUM stock, go to TipRanks’ Stock Analysis page.